LCT and cancer: These results hold promise for the potential use of α-CDE (G3, DS 2.4), Lac-α-CDE (G3, DSL 1.2) and Fol-PαC (G3, DSF 4) as a universal, a hepatocyte-selective and FR-overexpressing cancer cell-selective carriers for siRNA, respectively, with negligible cytotoxicity.